Corey Ostman

Corey Ostman
deal fairly fast food good portfolio price regional retailers somewhat sort spark
They have a good portfolio of fairly well-known retailers in the fast food market, they're somewhat regional in the South, and that will be enough to spark some interest. But it's not a deal that will see any sort of price movement.
market wants
Semiconductors are not what the market wants to see right now.
brand example good
This is an example of a pretty good brand name. It just wasn't interesting.
hearing interested moderate reasonably sorts
Institutions are always interested in hearing about these sorts of deal. They could do reasonably well and see a moderate pop.
coming time
They are coming out at the right time in the market.
among brand decent demand developing seem
The interesting thing is that they seem to be developing pretty decent brand recognition among consumers. It does show that there is some demand for more non-infrastructure issues.
course deal expect jump
It is an NYSE deal and of course you don't expect to see a lot of jump with those.
gets given last market slow slower start year
Every year the IPO market gets off to a slow start, and given last year's performance, it should get off to an even slower start this year.
demand odyssey unknown
Odyssey is in wait-and-see mode. It's kind of unknown what the institutional demand will be.
created good publicity type
It has created the type of publicity that a good IPO needs.
dynamics great hard hype invest predict
The dynamics of an IPO, especially one with the hype like this one, is always hard to predict right out of the gate. But this is a great company. It's one a lot of institutions are going to want to invest in.
early market rebound
It's too early for a rebound though, and the market is still very selective.
given imagine investors welcome
Given the skittishness I would imagine a lot of investors would welcome this.
general
After the genomic (breakthrough) biotech in general has been doing really well.